FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA

被引:0
|
作者
Lazaridis, L. [1 ,2 ]
Schmidt, T. [1 ,2 ]
Agkatsev, S. [1 ,2 ]
Blau, T. [3 ]
Spille, D. [4 ]
Heider, S. [5 ]
Schulz, T. [6 ]
Bumes, E. [7 ]
Oster, C. [1 ,2 ]
Feldheim, J. [1 ,2 ]
Stummer, W.
Kessler, A. [6 ]
Seidel, C. [5 ]
Hau, P. [7 ]
Sure, U. [8 ]
Keyvani, K. [3 ]
Herrlinger, U. [9 ]
Kleinschnitz, C. [1 ,2 ]
Stuschke, M. [10 ]
Herrmann, K. [11 ]
Deuschl, C. [12 ]
Hattingen, E. [13 ]
Scheffler, B. [14 ]
Kebir, S. [1 ,2 ]
Glas, M. [1 ,2 ]
机构
[1] Univ Med Essen, Div Clin Neurooncol, Ctr Translat Neuro & Behav Sci C TN, Essen, Germany
[2] Univ Med Essen, Dept Neurol, Essen, Germany
[3] Univ Med Essen, Inst Neuropathol, Essen, Germany
[4] Univ Hosp Munster, Dept Neurosurg, Munster, Germany
[5] Univ Hosp Leipzig, Dept Radiotherapy & Radiat Oncol, Leipzig, Germany
[6] Univ Hosp Wurzburg, Dept Neurosurg, Wurzburg, Germany
[7] Univ Hosp Regensburg, Dept Neurol & Wilhelm Sander NeuroOncol Unit, Regensburg, Germany
[8] Univ Med Essen, Dept Neurosurg & Spine Surg, Essen, Germany
[9] Univ Hosp Bonn, Div Clin Neurooncol, Dept Neurol & Ctr Integrated Oncol, Bonn, Germany
[10] Univ Med Essen, Dept Radiotherapy, Essen, Germany
[11] Univ Med Essen, Dept Nucl Med, Essen, Germany
[12] Univ Med Essen, Inst Diagnost & Intervent Radiol & Neurora, Essen, Germany
[13] Univ Hosp Frankfurt, Inst Neuroradiol, Frankfurt, Germany
[14] Univ Med Essen, West German Canc Ctr WTZ, DKFZ Div Translat Neurooncol, DKTK Partner Site, Essen, Germany
关键词
D O I
10.1093/neuonc/noac174.204
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P11.15.B
引用
收藏
页数:2
相关论文
共 50 条
  • [41] QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS
    Herrlinger, Ulrich
    Schaefer, Niklas
    Steinbach, Joachim
    Weyerbrock, Astrid
    Hau, Peter
    Goldbrunner, Roland
    Kohnen, Ralf
    Urbach, Horst
    Stummer, Walter
    Glas, Martin
    NEURO-ONCOLOGY, 2014, 16
  • [42] Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
    Weller, M.
    Gramatzki, D.
    Felsberg, J.
    Hentschel, B.
    Wolter, M.
    Schackert, G.
    Westphal, M.
    Regli, L.
    Thon, N.
    Tatagiba, M.
    Wick, W.
    Schlegel, U.
    Krex, D.
    Roth, P.
    Rushing, E.
    Pietsch, T.
    von Deimling, A.
    Sabel, M.
    Loeffler, M.
    Reifenberger, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S396 - S396
  • [43] FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
    Frenel, J-S.
    Cartron, P-F.
    Gourmelon, C.
    Campion, L.
    Aumont, M.
    Augereau, P.
    Ducray, F.
    Loussouarn, D.
    Lallier, L.
    Robert, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S400 - S400
  • [44] Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.
    Herrlinger, Ulrich
    Schaefer, Niklas
    Steinbach, Joachim Peter
    Weyerbrock, Astrid
    Hau, Peter
    Goldbrunner, Roland
    Friedrich, Franziska
    Stockhammer, Florian
    Ringel, Florian
    Braun, Christian
    Kohnen, Ralf
    Leutgeb, Barbara
    Belka, Claus
    Urbach, Horst
    Stummer, Walter
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] PHASE I TRIAL OF DRUG RESISTANT IMMUNOTHERAPY: A FIRST-IN-CLASS COMBINATION OF MGMT-MODIFIED γδ T CELLS AND TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Lamb, Lawrence
    Markert, James
    Gillespie, G. Yancey
    Beelen, Melissa
    Langford, Catherine
    Pereboeva, Larisa
    Youngblood, Samantha
    Nabors, Louis
    NEURO-ONCOLOGY, 2019, 21 : 6 - 6
  • [46] Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
    Nabors, Louis B.
    Lamb, Lawrence S.
    Beelen, Melissa Jo
    Pillay, Thriumaine
    ter Haak, Mariska
    Youngblood, Samantha
    Vaickus, Louis
    Lobbous, Mina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] A Novel Recursive Partitioning Analysis Classification in Newly Diagnosed Glioblastoma Patients Treated With Radiation Therapy and Temozolomide: Highlighting the MGMT Promoter Methylation Status
    Wee, C. W.
    Kim, E.
    Kim, I. H.
    Kim, I. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E85 - E85
  • [48] Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
    Wick, Wolfgang
    Gorlia, Thierry
    Bady, Pierre
    Platten, Michael
    van den Bent, Martin J.
    Taphoorn, Martin J. B.
    Steuve, Jonathan
    Brandes, Alba A.
    Hamou, Marie-France
    Wick, Antje
    Kosch, Markus
    Weller, Michael
    Stupp, Roger
    Roth, Patrick
    Golfinopoulos, Vassilis
    Frenel, Jean-Sebastien
    Campone, Mario
    Ricard, Damien
    Marosi, Christine
    Villa, Salvador
    Weyerbrock, Astrid
    Hopkins, Kirsten
    Homicsko, Krisztian
    Lhermitte, Benoit
    Pesce, Gianfranco
    Hegi, Monika E.
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4797 - 4806
  • [49] THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE
    Herrlinger, U.
    Schaefer, N.
    Steinbach, J. P.
    Weyerbrock, A.
    Hau, P.
    Goldbrunner, R.
    Leutgeb, B.
    Urbach, H.
    Stummer, W.
    Glas, M.
    NEURO-ONCOLOGY, 2014, 16
  • [50] Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas
    Gessler, Florian
    Bernstock, Joshua D.
    Braczynski, Anne
    Lescher, Stephanie
    Baumgarten, Peter
    Harter, Patrick N.
    Mittelbronn, Michel
    Wu, Tianxia
    Seifert, Volker
    Senft, Christian
    NEUROSURGERY, 2019, 84 (01) : 190 - 197